BridgeBio Pharma (NASDAQ:BBIO) has reported promising results from its Phase 2 trial of infigratinib for achondroplasia.
The investigational therapy showed a significant and sustained increase in annualized height velocity (AHV) at both 12 and 18 months in children, along with improvements in body proportionality.
“These data indicate that treatment with infigratinib is continuing to show increased growth velocity and improvements in body proportionality in children with achondroplasia,” said Dr. Ravi Savarirayan, global lead investigator for the study.
He confirmed that infigratinib continues to be well-tolerated, with no adverse events assessed as treatment-related in the participants.
Meanwhile, the company's global Phase 3 registrational study, PROPEL 3, is also progressing on schedule, with completion anticipated by the end of 2024.
Dr. Savarirayan expressed optimism about the study's potential, noting, “We hope to see these improvements reflected in the ongoing PROPEL 3 pivotal study.”